HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Seneca, H. Articles by Henderson, E. Search for Related Content PubMed Articles by Seneca, H. Articles by Henderson, E.

Phthalylsulfacetimide (Thalamyd) in Cholera

Since cholera is characterized by acute salt and water depletion, and severe general toxemia, the therapeutic problems are to restore fluid and salt, and to eradicate the infecting organism. In addition, special measures are being employed to protect body systems against the toxemia, such as the use of testosterone for its effect on the kidney (8).

In 1947 cholera appeared in Egypt for the first time since 1902, reaching epidemic proportions during September and forming a total of 21,661 cases by the end of December (14). The mortality was 10,696 or 49.4 per cent. During this epidemic, we were able to treat more than one hundred patients with phthalylsulfacetimide, but, owing to well known difficulties prevailing in any cholera epidemic, we have complete records for only forty. In this series of forty cases, there was one death, or 2.5 per cent. For reasons which will be made plain, we do not stress comparative mortality figures, nor insist upon the validity of statistics purporting to evalute a drug during a raging epidemic.

¹ From the College of Physicians and Surgeons, Columbia University, New York, N. Y.

² Clinical Research Division, Schering Corporation, Bloomfield, New Jersey.